OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Nanomaterial Delivery Systems for mRNA Vaccines
Michael D. Buschmann, Manuel Carrasco, Suman Alishetty, et al.
Vaccines (2021) Vol. 9, Iss. 1, pp. 65-65
Open Access | Times Cited: 446

Showing 1-25 of 446 citing articles:

mRNA-lipid nanoparticle COVID-19 vaccines: Structure and stability
Linde Schoenmaker, Dominik Witzigmann, Jayesh A. Kulkarni, et al.
International Journal of Pharmaceutics (2021) Vol. 601, pp. 120586-120586
Open Access | Times Cited: 1001

mRNA vaccines for infectious diseases: principles, delivery and clinical translation
Namit Chaudhary, Drew Weissman, Kathryn A. Whitehead
Nature Reviews Drug Discovery (2021) Vol. 20, Iss. 11, pp. 817-838
Open Access | Times Cited: 939

The clinical progress of mRNA vaccines and immunotherapies
Ann Barbier, Allen Yujie Jiang, Peng Zhang, et al.
Nature Biotechnology (2022) Vol. 40, Iss. 6, pp. 840-854
Open Access | Times Cited: 468

Chemistry of Lipid Nanoparticles for RNA Delivery
Yulia Eygeris, Mohit Gupta, Jeonghwan Kim, et al.
Accounts of Chemical Research (2021) Vol. 55, Iss. 1, pp. 2-12
Closed Access | Times Cited: 453

Advances in COVID-19 mRNA vaccine development
Enyue Fang, Xiaohui Liu, Miao Li, et al.
Signal Transduction and Targeted Therapy (2022) Vol. 7, Iss. 1
Open Access | Times Cited: 392

The mRNA-LNP platform's lipid nanoparticle component used in preclinical vaccine studies is highly inflammatory
Sonia Ndeupen, Zhen Qin, Sonya Jacobsen, et al.
iScience (2021) Vol. 24, Iss. 12, pp. 103479-103479
Open Access | Times Cited: 379

An ionizable lipid toolbox for RNA delivery
Xuexiang Han, Hanwen Zhang, Kamila Butowska, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 343

IL-1 and IL-1ra are key regulators of the inflammatory response to RNA vaccines
Siri Tähtinen, Ann-Jay Tong, Patricia Himmels, et al.
Nature Immunology (2022) Vol. 23, Iss. 4, pp. 532-542
Open Access | Times Cited: 325

Mechanisms of innate and adaptive immunity to the Pfizer-BioNTech BNT162b2 vaccine
Chunfeng Li, Audrey Lee, Lilit Grigoryan, et al.
Nature Immunology (2022) Vol. 23, Iss. 4, pp. 543-555
Open Access | Times Cited: 312

The landscape of mRNA nanomedicine
Xiangang Huang, Na Kong, Xingcai Zhang, et al.
Nature Medicine (2022) Vol. 28, Iss. 11, pp. 2273-2287
Open Access | Times Cited: 305

Structural parameters of nanoparticles affecting their toxicity for biomedical applications: a review
Reza Abbasi, Ghazal Shineh, Mohammadmahdi Mobaraki, et al.
Journal of Nanoparticle Research (2023) Vol. 25, Iss. 3
Open Access | Times Cited: 286

Passive, active and endogenous organ-targeted lipid and polymer nanoparticles for delivery of genetic drugs
Sean A. Dilliard, Daniel J. Siegwart
Nature Reviews Materials (2023) Vol. 8, Iss. 4, pp. 282-300
Open Access | Times Cited: 274

Role of nanotechnology behind the success of mRNA vaccines for COVID-19
Amit Khurana, Prince Allawadhi, Isha Khurana, et al.
Nano Today (2021) Vol. 38, pp. 101142-101142
Open Access | Times Cited: 220

Nucleic acid delivery for therapeutic applications
Akash Gupta, Jason L. Andresen, Rajith S. Manan, et al.
Advanced Drug Delivery Reviews (2021) Vol. 178, pp. 113834-113834
Closed Access | Times Cited: 214

Strategies for HIV-1 vaccines that induce broadly neutralizing antibodies
Barton F. Haynes, Kevin Wiehe, Persephone Borrow, et al.
Nature reviews. Immunology (2022) Vol. 23, Iss. 3, pp. 142-158
Open Access | Times Cited: 211

COVID-19 mRNA vaccines: Platforms and current developments
Gábor Szabó, Azita J. Mahiny, Irena Vlatkovic
Molecular Therapy (2022) Vol. 30, Iss. 5, pp. 1850-1868
Open Access | Times Cited: 194

Principles for designing an optimal mRNA lipid nanoparticle vaccine
Edo Kon, Uri Elia, Dan Peer
Current Opinion in Biotechnology (2021) Vol. 73, pp. 329-336
Open Access | Times Cited: 181

A Comprehensive Review of mRNA Vaccines
Vrinda Gote, Pradeep Kumar Bolla, Nagavendra Kommineni, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 3, pp. 2700-2700
Open Access | Times Cited: 180

mRNA Vaccines in the COVID-19 Pandemic and Beyond
Michael J. Hogan, Norbert Pardi
Annual Review of Medicine (2021) Vol. 73, Iss. 1, pp. 17-39
Open Access | Times Cited: 177

Difference in the lipid nanoparticle technology employed in three approved siRNA (Patisiran) and mRNA (COVID-19 vaccine) drugs
Yuta Suzuki, Hiroshi Ishihara
Drug Metabolism and Pharmacokinetics (2021) Vol. 41, pp. 100424-100424
Open Access | Times Cited: 175

The Critical Contribution of Pseudouridine to mRNA COVID-19 Vaccines
Pedro Morais, Hironori Adachi, Yi‐Tao Yu
Frontiers in Cell and Developmental Biology (2021) Vol. 9
Open Access | Times Cited: 175

Lyophilization provides long-term stability for a lipid nanoparticle-formulated, nucleoside-modified mRNA vaccine
Hiromi Muramatsu, Kieu Lam, Csaba Bajusz, et al.
Molecular Therapy (2022) Vol. 30, Iss. 5, pp. 1941-1951
Open Access | Times Cited: 167

Lipid Nanoparticle (LNP) Enables mRNA Delivery for Cancer Therapy
Yan Zong, Yi Lin, Tuo Wei, et al.
Advanced Materials (2023) Vol. 35, Iss. 51
Closed Access | Times Cited: 161

Page 1 - Next Page

Scroll to top